Cytotoxicity of cis-parinaric acid in cultured malignant gliomas.
The cytotoxic effects of cis-parinaric acid, a plant-derived 18-carbon polyunsaturated fatty acid, were assessed in vitro on normal and neoplastic glia. After being incubated for 24 hours in the presence of 12 mumol/L cis-parinaric acid, 36B10 glioma cultures demonstrated nearly 90% toxicity (unpaired Student's t test, P < 0.001). Similar results were obtained after the exposure of C6 rat glioma cultures, A172 human glioma cultures, and U-937 human monocytic leukemia cultures to cis-parinaric acid. In contrast, fetal rat astrocytes incubated with 12 mumol/L cis-parinaric acid demonstrated no significant toxicity (3% reduction, P = 0.12); fetal rat astrocytes showed only 20% toxicity after exposure to 40 mumol/L cis-parinaric acid (P = 0.001). The cytotoxic effects of cis-parinaric acid were antagonized with the addition of equimolar concentrations of alpha-tocopherol. Enzyme immunoassay of treated 36B10 glioma supernatant fluid for 8-isoprostane (a known oxidative metabolite) demonstrated a 10-fold increase of 8-isoprostane over 24 hours (123.0 +/- 10.3 versus 10.0 +/- 0.7 pg/ml for control, P < 0.001). These studies indicate that cis-parinaric acid may be significantly cytotoxic to malignant glioma cells in concentrations that spare normal astrocytes and that the mechanism of cytotoxicity is related to an oxidative process. The selective cytotoxic effect of cis-parinaric acid we describe represents the first step in the development of new chemotherapeutic agents for gliomas; these new agents act by preferentially enhancing lipid peroxidation in neoplastic cells.
Traynelis
V C
VC
Department of Surgery, University of Iowa College of Medicine, Iowa City, USA.
Ryken
T C
TC
Cornelius
A S
AS
D000818:Animals; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000494:pharmacology*; D001095:Arachidonic Acids / Q000493:pharmacokinetics; D001253:Astrocytes / Q000187:drug effects / Q000473:pathology; D001932:Brain Neoplasms / Q000473:pathology*; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects* / Q000502:physiology; D015237:Dinoprost / Q000031:analogs & derivatives*; D004305:Dose-Response Relationship, Drug; D028441:F2-Isoprostanes; D005231:Fatty Acids, Unsaturated / Q000493:pharmacokinetics / Q000494:pharmacology*; D005910:Glioma / Q000473:pathology*; D006801:Humans; D015227:Lipid Peroxidation / Q000187:drug effects; D051381:Rats; D014407:Tumor Cells, Cultured / Q000187:drug effects* / Q000473:pathology
D000970:Antineoplastic Agents; D001095:Arachidonic Acids; D028441:F2-Isoprostanes; D005231:Fatty Acids, Unsaturated; C075750:8-epi-prostaglandin F2alpha; D015237:Dinoprost; C013641:parinaric acid